1. Home
  2. MBIO vs ENSC Comparison

MBIO vs ENSC Comparison

Compare MBIO & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MBIO
  • ENSC
  • Stock Information
  • Founded
  • MBIO 2015
  • ENSC 2003
  • Country
  • MBIO United States
  • ENSC United States
  • Employees
  • MBIO N/A
  • ENSC N/A
  • Industry
  • MBIO Biotechnology: Pharmaceutical Preparations
  • ENSC Biotechnology: Pharmaceutical Preparations
  • Sector
  • MBIO Health Care
  • ENSC Health Care
  • Exchange
  • MBIO Nasdaq
  • ENSC Nasdaq
  • Market Cap
  • MBIO 9.1M
  • ENSC 7.9M
  • IPO Year
  • MBIO N/A
  • ENSC N/A
  • Fundamental
  • Price
  • MBIO $0.18
  • ENSC $8.88
  • Analyst Decision
  • MBIO Strong Buy
  • ENSC
  • Analyst Count
  • MBIO 1
  • ENSC 0
  • Target Price
  • MBIO $2.00
  • ENSC N/A
  • AVG Volume (30 Days)
  • MBIO 659.9K
  • ENSC 179.0K
  • Earning Date
  • MBIO 11-08-2024
  • ENSC 11-12-2024
  • Dividend Yield
  • MBIO N/A
  • ENSC N/A
  • EPS Growth
  • MBIO N/A
  • ENSC N/A
  • EPS
  • MBIO N/A
  • ENSC N/A
  • Revenue
  • MBIO N/A
  • ENSC $4,421,404.00
  • Revenue This Year
  • MBIO N/A
  • ENSC $12.04
  • Revenue Next Year
  • MBIO N/A
  • ENSC N/A
  • P/E Ratio
  • MBIO N/A
  • ENSC N/A
  • Revenue Growth
  • MBIO N/A
  • ENSC 40.41
  • 52 Week Low
  • MBIO $0.13
  • ENSC $2.12
  • 52 Week High
  • MBIO $1.53
  • ENSC $30.90
  • Technical
  • Relative Strength Index (RSI)
  • MBIO 45.42
  • ENSC 55.87
  • Support Level
  • MBIO $0.16
  • ENSC $5.96
  • Resistance Level
  • MBIO $0.18
  • ENSC $10.96
  • Average True Range (ATR)
  • MBIO 0.02
  • ENSC 1.29
  • MACD
  • MBIO 0.00
  • ENSC 0.29
  • Stochastic Oscillator
  • MBIO 55.37
  • ENSC 62.99

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: